These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24596453)

  • 21. Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein.
    Torrey HL; Kaliaperumal V; Bramhecha Y; Weir GM; Falsey AR; Walsh EE; Langley JM; Schepens B; Saelens X; Stanford MM
    Hum Vaccin Immunother; 2020 Sep; 16(9):2007-2017. PubMed ID: 32530723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
    Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Teates D; Neese P; Grosh WW; Petroni G; Engelhard VH; Slingluff CL
    Int J Cancer; 2001 Jun; 92(5):703-11. PubMed ID: 11340576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.
    Morse MA; Secord AA; Blackwell K; Hobeika AC; Sinnathamby G; Osada T; Hafner J; Philip M; Clay TM; Lyerly HK; Philip R
    Clin Cancer Res; 2011 May; 17(10):3408-19. PubMed ID: 21300761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of highly activated, antigen-specific tumor-infiltrating CD8
    Vila-Leahey A; MacKay A; Portales-Cervantes L; Weir GM; Merkx-Jacques A; Stanford MM
    Oncoimmunology; 2020 Jun; 9(1):1782574. PubMed ID: 32923145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.
    Suzuki H; Fukuhara M; Yamaura T; Mutoh S; Okabe N; Yaginuma H; Hasegawa T; Yonechi A; Osugi J; Hoshino M; Kimura T; Higuchi M; Shio Y; Ise K; Takeda K; Gotoh M
    J Transl Med; 2013 Apr; 11():97. PubMed ID: 23578144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
    Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
    Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlates of immune and clinical activity of novel cancer vaccines.
    van der Burg SH
    Semin Immunol; 2018 Oct; 39():119-136. PubMed ID: 29709421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
    Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
    J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
    Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
    Front Immunol; 2018; 9():2968. PubMed ID: 30631324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal
    Weir GM; MacDonald LD; Rajagopalan R; Sivko GS; Valderas MW; Rayner J; Berger BJ; Sammatur L; Stanford MM
    NPJ Vaccines; 2019; 4():6. PubMed ID: 30774997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers.
    Otterhaug T; Janetzki S; Welters MJP; Håkerud M; Nedberg AG; Edwards VT; Boekestijn S; Loof NM; Selbo PK; Olivecrona H; van der Burg SH; Høgset A
    Front Immunol; 2020; 11():576756. PubMed ID: 33488576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients.
    Chai SJ; Fong SCY; Gan CP; Pua KC; Lim PVH; Lau SH; Zain RB; Abraham T; Ismail SM; Abdul Rahman ZA; Ponniah S; Patel V; Cheong SC; Lim KP
    Hum Vaccin Immunother; 2019; 15(1):167-178. PubMed ID: 30193086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.
    Banchereau J; Ueno H; Dhodapkar M; Connolly J; Finholt JP; Klechevsky E; Blanck JP; Johnston DA; Palucka AK; Fay J
    J Immunother; 2005; 28(5):505-16. PubMed ID: 16113607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using lymph node swelling as a potential biomarker for successful vaccination.
    Brewer KD; DeBay DR; Dude I; Davis C; Lake K; Parsons C; Rajagopalan R; Weir G; Stanford MM; Mansour M; Bowen CV
    Oncotarget; 2016 Jun; 7(24):35655-35669. PubMed ID: 27232944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.